MOU Signed Between GENOCURE & COSMAXPHARMA, for PDRN-based Regenerativ…
페이지 정보
작성자Admin 조회 106 views 작성일 2024-08-23본문
MOU Signed between GENOCURE & COSMAXPHARMA,
for PDRN-based Regenerative Medicine Business
Promoting joint projects related to PDRN that shows excellent effects
in cell regeneration and wound treatment
2024-01-29 10:03
GENOCURE Co., Ltd. (CEO Oh Bo Kyung and Lim Hye Won) and COSMAXPHARMA Co., Ltd. (CEO Lee Ho Kyung) signed a business agreement for a 'PDRN-based regenerative medicine business'.
GENOCURE is a startup bio venture company that possesses the technology to extract and produce high-purity PDRN(Polydeoxyribonucleotide) and is actively entering the regenerative medicine market by supplying PDRN as a raw material for medical devices and cosmetics and developing finished products related to it.
Oh Bo Kyung, CEO of GENOCURE, plans to extract and produce high-purity domestic PDRN in large quantities from 2024 and supply it as the largest in Korea. Also, through bGMP certification from the Ministry of Food and Drug Safety, the company plans to mass produce and supply the highest-quality PDRN as a raw material pharmaceutical standard.
COSMAXPHARMA highly values GENOCURE's outstanding technology and ability to stably produce mass amounts of high-purity PDRN and has established a strategic partnership to develop, market and distribute for comprehensive regenerative medicine business, including not only raw pharmaceuticals and cosmetics but also medical devices, health functional foods, and pharmaceuticals, thorugh PDRN raw materials.
Accordingly, the two companies stated that they would lead the beauty/healthcare industry through 'various regenerative medical projects using PDRN' through this business agreement.
Reporter, Kim Chang Won (kimcw@medipana.com)
<Ⓒ 2024 Medipana, Unauthorized reproduction and distribution prohibited>
'The center of Korean medical news' Medipana News